medigraphic.com
Instituto Nacional de Salud Pública

2013, Number 5

<< Back Next >>

salud publica mex 2013; 55 (5)

Carcinoma in situ e infiltrante identificado por tamizaje mamográfico oportunista en mujeres asintomáticas de la Ciudad de México

Reynoso-Noverón N, Villaseñor-Navarro Y, Hernández-Ávila M, Mohar-Betancourt A

Language: Spanish
References: 48
Page: 469-477
PDF size: 198.24 Kb.


ABSTRACT

Objective. To describe the mammographic findings and carcinoma detection rate in asymptomatic women of Mexico City, that participated in an opportunistic screening program. Materials and methods. 39 491 participants were included, with mammograms performed and interpreted in the National Cancer Institute, from 2008 to 2011. The mammographic findings, type of lesion and true positives (TP), are described by age groups. We calculated the crude effect of age on the classification BIRADS (Breast Imaging Reporting and Data System) 0 and the type of lesion. Results. The median age was 50 (45-57) years. 80.5% were classified as BIRADS 2, 11.4%(0), 4.1%(1), 3.5%(3), 0.5%(4) y 0.1%(5). Malignant lesions were detected in 1.3 and 3.3 per 1000 and the proportion of true positives (TP) was 8.2% and 20.6%, in women of 41-50 and 51-70 years, respectively. Conclusions. Although some cases are detected in women 40 to 50 years, in women over 50 years the screening by mammography is more efficient, with a higher proportion of cases detected and fewer false positives.


REFERENCES

  1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al., eds. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute, 2004:1975-2001. [Consultado el 11 de abril de 2008]. Disponible en http://seer.cancer.gov/csr/1975_2001.

  2. Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer Incidence in Five Continents, vols. I–VIII. IARC Cancer Base no. 6. Lyon, France: IARC Press, 2005. [Consultado el 25 de noviembre de 2009]. Disponible en http://www-dep.iarc.fr.

  3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.

  4. International Agency for Research on Cancer. GLOBOCAN 2008. [Consultado en octubre de 2012]. Disponible en: http://www-dep.iarc.fr/

  5. Rodríguez-Cuevas S, Macías CG, Franceschi D, Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer 2001;91:863-868.

  6. De la Vara-Salazar E, Suárez-López L, Ángeles-Llerenas A, Torres-Mejía G, Lazcano-Ponce E. Tendencias de la mortalidad por cáncer de mama en México, 1980-2009. Salud Publica Mex 2011;53:385-393

  7. Organización Mundial de la Salud. Cáncer. Nota Descriptiva No.297. OMS; 2012 [Consultado el 25 de octubre de 2012]. Disponible en: http:// www.who.int/mediacentre/factsheets/fs297/es/index.html

  8. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003;39:1718-1729.

  9. Robles SC, Galanis E. Breast cancer in Latin America and the Caribbean. Rev Panam Salud Publica/Pan Am J Public Health 2002;11(3):178-184.

  10. McPherson K, Steel CM, Dixon JM. Breast cancer – epidemiology, risk factors and genetics. BMJ 2000; 321:624-628.

  11. Lopez-Carrillo L, Torres-Sánchez L, López-Cervantes M, Rueda-Neria C. Identificación de lesiones mamarias malignas en Mexico. Salud Publica Mex 2001; 43:199-202.

  12. González-Pier E, Gutiérrez-Delgado C, Stevens G, Barraza-Lloréns M, Porras-Condey R, Carvalho N, et al. Definición de prioridades para las intervenciones de salud en el Sistema de Protección Social en Salud de México. Salud Publica Mex 2007;49 (Supl. 1):S37-S52.

  13. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-Negative Breast Cancer in Hispanic Patients. Cancer 2011; 117: 3658-3669.

  14. Harford JB. Breast-cancer early detection in low-income and middleincome countries: do what you can versus one size fits all. Lancet Oncol 2011;12(3):306-312.

  15. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, et al. Second consensus on medical treatment of metastatic breast cancer – CECOG guidelines. Ann Oncol 2007;18(2):215-225.

  16. Consenso Nacional sobre Diagnóstico y Tratamiento del cáncer mamario. Cuarta revisión. Colima, México: Masson Doyma México, 2011.

  17. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137(5 part 1):347-360.

  18. Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med 2003;348(17):1672-1680.

  19. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005;353(17):1773-1783. [Epub 2005 Sep 16].

  20. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353(17):1784-1792.

  21. Saltzmann P, Kerlikowske K, Phillips K. Cost effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997;127(11):955-965.

  22. International Agency for Research on Cancer. Breast Cancer Screening. IARC. Handbooks of Cancer Prevention, Lyon: IARC Press, 2002;vol 7.

  23. Advisory Committee on Breast Cancer Screening. Screening for breast cancer in England: past and future. NHSBSP Publication No 61. February 2006. Prepress Projects Ltd, Perth. [Consultado en octubre de 2008]. Disponible en: www.prepress-projects.co.uk.

  24. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA 1995; 273(2):149-154.

  25. Tabar L, Yen MF, Vitak B, Chen HHT, Smith RA, Duffy SW. Mamography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction and screening. Lancet 2003; 361:1405-1410.

  26. Olsen O, Gozsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358:1340-1342.

  27. Preventive Services Task Force. Screening for breast cancer U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:716-726.

  28. Autier P, Koechlin A, Smans M, Vatten L, Boniol M. Mammography screening and breast cancer mortality in Sweden. J Natl Cancer Inst 2012;104(14):1080-1093.

  29. NOM-041-SSA2-2011, Para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cancer de mama. Diario Oficial de la Federación, 09 junio 2006. [Consultado en septiembre de 2012] Disponible en: http://dof.gob.mx/nota_detalle_popup.php?codigo=5194157

  30. American College of Radiology (ACR) Breast imaging reporting and data system: ACK BI-RADS. Breast imaging atlas. Reston VA: American College of Radiology, 2003.

  31. Ortega-Altamirano D, Lopez-Cervantes M. Estrategias de la enseñanza de auto examen del seno en mujeres en edad reproductiva. Salud Publica Mex 2000; 42:17-25.

  32. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002;94:1445-1457.

  33. Díaz S, Piñeros M, Sánchez O. Early detection of breast cancer: critical aspects for an organized screening programme in Colombia. Rev Colomb Cancerol 2005;9:93-105.

  34. Berg W, Blume J, Cormack J, Mendelson E, Lehrer E, Böhm-Vélez M, et al. Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer. JAMA 2008; 299(18):2151-2163.

  35. Elmore JG, Sickles EA, Buist DS, Miglioretti DL, Carney PA, Geller B, et al. Variability in interpretive performance at screening mammography and radiologists characteristics associated with accuracy. Radiology 2009;253(3):641-651. Epub 2009 Oct 28.

  36. Schell MJ, Yankaskas BC, Ballard-Barbash R, Qaqish BF, Barlow WE, Rosenberg RD, et al. Evidence-based target recall rates for screening mammography. Radiology 2007:243(3):681-689.

  37. Smith-Bindman R, Chu PW, Miglioretti DL. Comparison of screening mammography in the United States and the United Kingdom. JAMA 2003;290:2129-2137.

  38. Roubidoux M, Bailey J, Wray L, Helvie M. Invasive cancers detected after breast cancer screening yielded a negative result: relationship of mammographic density to tumor prognostic factors. Radiology 2004; 230:42-48.

  39. Jimenez-Lee R, Oslak SG, Hedberg K, Vetto JT. Surgical outcomes of a breast cancer-screening program for low-income women. Arch Surg 2003;138:884-890.

  40. Cortesi L, Chiuri VE, Ruscelli S, Bellelli V, Negri R, Rashid I, et al. Prognosis of screen detected breast cancers: results of a population based study. BMC Cancer 2006;6:17.

  41. Junkermann H, Becker N, Peitgen HO. Concept and implementation of model projects for mammography screening in Germany. Radiologie 2001;41:328-336

  42. Ohnuki K. Mammographic screening for non-palpable breast cancer in Japan. Breast Cancer 2005;12:258-266.

  43. Valencia-Mendoza A, Sánchez-González G, Bautista-Arredondo S, Torres-Mejía G, Bertozzi SM. Costo-efectividad de políticas para el tamizaje de cáncer de mama en México. Salud Publica Mex 2009;51 supl 2:S296-S304.

  44. Brett J, Austoker J. Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting reattendance. J Public Health Med 2001;23:292-300.

  45. Christiansen C, Wang F, Barton MB, Kreuter W, Elmore JG, Gelfand AE, et al. Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst 2000;92:1657-1666.

  46. Lidegaard O, Kroman N. The epidemiology of breast cancer. Eur Clinics Obstet Gynaecol 2005;1:24-28.

  47. Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study: A report from the EMBRACE, GENESPO, GEO-HEBON, and IBCCS Collaborator´s Group. J Clinical Oncology 2006; 24: 3361-3366.

  48. Gelder R, Heijnsdijk E, Ravesteyn N, Fracheboud J, Draisma G, de Koning HJ. Interpreting Overdiagnosis Estimates in Population-based Mammography Screening. Epidemiol Rev 2011;33:111-121.




2020     |     www.medigraphic.com